315 results on '"Stéphane Bonacorsi"'
Search Results
2. Early-Onset Infection Caused by Escherichia coli Sequence Type 1193 in Late Preterm and Full-Term Neonates
- Author
-
Célie Malaure, Guillaume Geslain, André Birgy, Philippe Bidet, Isabelle Poilane, Margaux Allain, Mathilde Liberge, Nizar Khattat, Paola Sikias, and Stéphane Bonacorsi
- Subjects
neonatal sepsis ,Escherichia coli ,bacteria ,antimicrobial resistance ,whole-genome sequencing ,meningitis/encephalitis ,Medicine ,Infectious and parasitic diseases ,RC109-216 - Abstract
Using whole-genome sequencing, we characterized Escherichia coli strains causing early-onset sepsis (EOS) in 32 neonatal cases from a 2019–2021 prospective multicenter study in France and compared them to E. coli strains collected from vaginal swab specimens from women in third-trimester gestation. We observed no major differences in phylogenetic groups or virulence profiles between the 2 collections. However, sequence type (ST) analysis showed the presence of 6/32 (19%) ST1193 strains causing EOS, the same frequency as in the highly virulent clonal group ST95. Three ST1193 strains caused meningitis, and 3 harbored extended-spectrum β-lactamase. No ST1193 strains were isolated from vaginal swab specimens. Emerging ST1193 appears to be highly prevalent, virulent, and antimicrobial resistant in neonates. However, the physiopathology of EOS caused by ST1193 has not yet been elucidated. Clinicians should be aware of the possible presence of E. coli ST1193 in prenatal and neonatal contexts and provide appropriate monitoring and treatment.
- Published
- 2024
- Full Text
- View/download PDF
3. Sporadic Shiga Toxin–Producing Escherichia coli–Associated Pediatric Hemolytic Uremic Syndrome, France, 2012–2021
- Author
-
Gabrielle Jones, Patricia Mariani-Kurkdjian, Aurélie Cointe, Stéphane Bonacorsi, Sophie Lefèvre, François-Xavier Weill, and Yann Le Strat
- Subjects
Escherichia coli ,hemolytic uremic syndrome ,Shiga toxin–producing Escherichia coli ,STEC ,epidemiologic surveillance ,space-time clustering ,Medicine ,Infectious and parasitic diseases ,RC109-216 - Abstract
Shiga toxin–producing Escherichia coli–associated pediatric hemolytic uremic syndrome (STEC-HUS) remains an important public health risk in France. Cases are primarily sporadic, and geographic heterogeneity has been observed in crude incidence rates. We conducted a retrospective study of 1,255 sporadic pediatric STEC-HUS cases reported during 2012–2021 to describe spatiotemporal dynamics and geographic patterns of higher STEC-HUS risk. Annual case notifications ranged from 109 to 163. Most cases (n = 780 [62%]) were in children 5 annual space-time clusters. The results of this study have numerous implications for outbreak detection and investigation and research perspectives to improve knowledge of environmental risk factors associated with geographic disparities in STEC-HUS in France.
- Published
- 2023
- Full Text
- View/download PDF
4. Diagnostic accuracy of a rapid nucleic acid test for group A streptococcal pharyngitis using saliva samples: protocol for a prospective multicenter study in primary care
- Author
-
Robert Touitou, Philippe Bidet, Constance Dubois, Henri Partouche, Stéphane Bonacorsi, Camille Jung, Robert Cohen, Corinne Levy, and Jérémie F. Cohen
- Subjects
Acute pharyngitis ,Sore throat ,Rapid antigen detection tests ,Rapid nucleic acid tests ,Group A streptococcus ,Primary care ,Medicine (General) ,R5-920 - Abstract
Abstract Background Group A streptococcus is found in 20–40% of cases of childhood pharyngitis; the remaining cases are viral. Streptococcal pharyngitis (“strep throat”) is usually treated with antibiotics, while these are not indicated in viral cases. Most guidelines recommend relying on a diagnostic test confirming the presence of group A streptococcus before prescribing antibiotics. Conventional first-line tests are rapid antigen detection tests based on throat swabs. Recently, rapid nucleic acid tests were developed; they allow the detection of elements of the genome of group A streptococcus. We hypothesize that these rapid nucleic acid tests are sensitive enough to be performed on saliva samples instead of throat swabs, which could be more convenient in practice. Methods This is a multicenter, prospective diagnostic accuracy study evaluating the performance of a rapid nucleic acid test for group A streptococcus (Abbott ID NOW STREP A2) in saliva, compared with a conventional pharyngeal rapid antigen detection test (EXACTO PRO STREPTATEST, lateral flow assay, comparator test), with a composite reference standard of throat culture and group A streptococcus PCR in children with pharyngitis in primary care (i.e., 27 primary care pediatricians or general practitioners). To ensure group A streptococcus is not missed, the salivary rapid nucleic acid test requires a minimally acceptable value of sensitivity (primary outcome) set at 80%. Assuming 35% of participants will have group A streptococcus, we will recruit 800 consecutive children with pharyngitis. Secondary outcomes will include difference in sensitivity between the pharyngeal rapid antigen detection test and the salivary rapid nucleic acid test; variability in sensitivity and specificity of the salivary rapid nucleic acid test with the level of McIsaac score; time to obtain the result of the salivary rapid nucleic acid test; patient, physician, and parents satisfaction; and barriers and facilitators to using rapid tests for group A streptococcus in primary care. Ethics and dissemination Approved by the Institutional Review Board “Comité de protection des personnes Ile de France I” (no. 2022-A00085-38). Results will be presented at international meetings and disseminated in peer-reviewed journals. Trial registration number ClinicalTrials.gov: NCT05521568.
- Published
- 2023
- Full Text
- View/download PDF
5. Fatal Meningitis from Shiga Toxin–Producing Escherichia coli in 2 Full-Term Neonates, France
- Author
-
Guillaume Geslain, Aurélie Cointe, Philippe Bidet, Céline Courroux, Soumeth Abasse, Patricia Mariani, and Stéphane Bonacorsi
- Subjects
Shiga toxin–producing Escherichia coli ,Shiga toxin ,Escherichia coli ,neonate ,newborn ,bacteria ,Medicine ,Infectious and parasitic diseases ,RC109-216 - Abstract
We report fatal meningitis in 2 neonates in France caused by Shiga toxin 1–producing Escherichia coli. Virulence factors capsular K1 antigen and salmochelin were present in both strains, potentially representing a new hybrid pathotype. Clinicians should remain aware of emerging pathotypes and design therapeutic strategies for neonatal E. coli infections.
- Published
- 2023
- Full Text
- View/download PDF
6. Antibiotic Resistance of Haemophilus influenzae in Nasopharyngeal Carriage of Children with Acute Otitis Media and in Middle Ear Fluid from Otorrhea
- Author
-
Zein Assad, Robert Cohen, Emmanuelle Varon, Corinne Levy, Stéphane Bechet, François Corrard, Andreas Werner, Naïm Ouldali, Stéphane Bonacorsi, and Alexis Rybak
- Subjects
Haemophilus influenzae ,nasopharyngeal carriage ,acute otitis media ,spontaneous perforation of the tympanic membrane ,antibiotic resistance ,children ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Haemophilus influenzae (Hi) is one of the leading bacteria implicated in childhood acute otitis media (AOM). Recent concerns have been raised about the emergence of Hi-resistant strains. We aimed to analyze the evolution of β-lactam resistance to Hi among strains isolated from nasopharyngeal carriage in children with AOM and in mild ear fluid (MEF) after the spontaneous perforation of the tympanic membrane (SPTM) in France. In this national ambulatory-based cohort study over 16 years, we analyzed the rate of Hi nasopharyngeal carriage and the proportion of β-lactam-resistant Hi strains over time using a segmented linear regression model. Among the 13,865 children (median [IQR] age, 12.7 [9.3–17.3] months; 7400 [53.4%] male) with AOM included from November 2006 to July 2022, Hi was isolated in 7311 (52.7%) children by nasopharyngeal sampling. The proportion of β-lactamase-producing and β-lactamase-negative, ampicillin-resistant (BLNAR) Hi strains in nasopharyngeal carriage remained stable during the study period. Among the 783 children (median [IQR] age, 20 [12.3–37.8] months; 409 [52.2%] male) with SPTM included from October 2015 to July 2022, Hi was isolated in 177 (22.6%) cases by MEF sampling. The proportions of β-lactamase-producing and BLNAR Hi strains did not significantly differ between nasopharyngeal (17.6% and 8.8%, respectively) and MEF (12.6% and 7.4%) samples. Accordingly, amoxicillin remains a valid recommendation as the first-line drug for AOM in France.
- Published
- 2023
- Full Text
- View/download PDF
7. Surging bloodstream infections and antimicrobial resistance during the first wave of COVID–19: a study in a large multihospital institution in the Paris region
- Author
-
Rishma Amarsy, David Trystram, Emmanuelle Cambau, Catherine Monteil, Sandra Fournier, Juliette Oliary, Helga Junot, Pierre Sabatier, Raphaël Porcher, Jérôme Robert, Vincent Jarlier, Guillaume Arlet, Laurence Armand Lefevre, Alexandra Aubry, Laurent Belec, Béatrice Bercot, Stéphane Bonacorsi, Vincent Calvez, Etienne Carbonnelle, Stéphane Chevaliez, Jean-Winoc Decousser, Constance Delaugerre, Diane Descamps, Florence Doucet-Populaire, Jean-Louis Gaillard, Antoine Garbarg- Chenon, Elyanne Gault, Jean-Louis Herrmann, Jérôme Le Goff, Jean-Christophe Lucet, Jean-Luc Mainardi, Anne-Geneviève Marcellin, Laurence Morand-Joubert, Xavier Nassif, Jean-Michel Pawlotsky, Anne-Marie Roque Afonso, Martin Rottman, Christine Rouzioux, Flore Rozenberg, François Simon, Nicolas Veziris, David Skurnik, Jean-Ralph Zahar, Guilene Barnaud, Typhaine Billard Pomares, Gaëlle Cuzon, Dominique Decré, Alexandra Doloy, Jean-Luc Donay, Laurence Drieux-Rouzet, Isabelle Durand, Agnès Ferroni, Vincent Fihman, Nicolas Fortineau, Camille Gomart, Nathalie Grall, Christelle Guillet Caruba, Françoise Jaureguy, Valérie Lalande, Luce Landraud, Véronique Leflon, Patricia Mariani, Liliana Mihaila, Didier Moissenet, Latifa Noussair, Isabelle Podglajen, Isabelle Poilane, Hélène Poupet, Emilie Rondinaud, Valérie Sivadon Tardy, Charlotte Verdet, Emmanuelle Vigier, and Sophie Vimont Billarant
- Subjects
COVID-19 ,Blood culture ,Bloodstream infection incidence ,Antibiotic consumption ,Antimicrobial resistance ,Infectious and parasitic diseases ,RC109-216 - Abstract
Objectives: This study measured the impact of the first wave of COVID-19 pandemic (COVID-19) (March–April 2020) on the incidence of bloodstream infections (BSIs) at Assistance Publique – Hôpitaux de Paris (APHP), the largest multisite public healthcare institution in France. Methods: The number of patient admission blood cultures (BCs) collected, number of positive BCs, and antibiotic resistance and consumption were analysed retrospectively for the first quarter of 2020, and also for the first quarter of 2019 for comparison, in 25 APHP hospitals (ca. 14 000 beds). Results: Up to a fourth of patients admitted in March–April 2020 in these hospitals had COVID-19. The BSI rate per 100 admissions increased overall by 24% in March 2020 and 115% in April 2020, and separately for the major pathogens (Escherichia coli, Klebsiella pneumoniae, enterococci, Staphylococcus aureus, Pseudomonas aeruginosa, yeasts). A sharp increase in the rate of BSIs caused by microorganisms resistant to third-generation cephalosporins (3GC) was also observed in March–April 2020, particularly in K. pneumoniae, enterobacterial species naturally producing inducible AmpC (Enterobacter cloacae...), and P. aeruginosa. A concomitant increase in 3GC consumption occurred. Conclusions: The COVID-19 pandemic had a strong impact on hospital management and also unfavourable effects on severe infections, antimicrobial resistance, and laboratory work diagnostics.
- Published
- 2022
- Full Text
- View/download PDF
8. A high-throughput sequencing approach identifies immunotherapeutic targets for bacterial meningitis in neonatesResearch in context
- Author
-
Stéphanie Pons, Eric Frapy, Youssouf Sereme, Charlotte Gaultier, François Lebreton, Andrea Kropec, Olga Danilchanka, Laura Schlemmer, Cécile Schrimpf, Margaux Allain, François Angoulvant, Hervé Lecuyer, Stéphane Bonacorsi, Hugues Aschard, Harry Sokol, Colette Cywes-Bentley, John J. Mekalanos, Thomas Guillard, Gerald B. Pier, Damien Roux, and David Skurnik
- Subjects
Neonatal meningitis ,Vaccine ,High-throughput sequencing ,E. coli K1 ,PNAG ,Medicine ,Medicine (General) ,R5-920 - Abstract
Summary: Background: Worldwide, Escherichia coli is the leading cause of neonatal Gram-negative bacterial meningitis, but full understanding of the pathogenesis of this disease is not yet achieved. Moreover, to date, no vaccine is available against bacterial neonatal meningitis. Methods: Here, we used Transposon Sequencing of saturated banks of mutants (TnSeq) to evaluate E. coli K1 genetic fitness in murine neonatal meningitis. We identified E. coli K1 genes encoding for factors important for systemic dissemination and brain infection, and focused on products with a likely outer-membrane or extra-cellular localization, as these are potential vaccine candidates. We used in vitro and in vivo models to study the efficacy of active and passive immunization. Results: We selected for further study the conserved surface polysaccharide Poly-β-(1-6)-N-Acetyl Glucosamine (PNAG), as a strong candidate for vaccine development. We found that PNAG was a virulence factor in our animal model. We showed that both passive and active immunization successfully prevented and/or treated meningitis caused by E. coli K1 in neonatal mice. We found an excellent opsonophagocytic killing activity of the antibodies to PNAG and in vitro these antibodies were also able to decrease binding, invasion and crossing of E. coli K1 through two blood brain barrier cell lines. Finally, to reinforce the potential of PNAG as a vaccine candidate in bacterial neonatal meningitis, we demonstrated that Group B Streptococcus, the main cause of neonatal meningitis in developed countries, also produced PNAG and that antibodies to PNAG could protect in vitro and in vivo against this major neonatal pathogen. Interpretation: Altogether, these results indicate the utility of a high-throughput DNA sequencing method to identify potential immunotherapy targets for a pathogen, including in this study a potential broad-spectrum target for prevention of neonatal bacterial infections. Fundings: ANR Seq-N-Vaq, Charles Hood Foundation, Hearst Foundation, and Groupe Pasteur Mutualité.
- Published
- 2023
- Full Text
- View/download PDF
9. Comparison between enzyme‐linked immunospot assay and intracellular cytokine flow cytometry assays for the evaluation of T cell response to SARS‐CoV‐2 after symptomatic COVID‐19
- Author
-
Juliette Villemonteix, Laure Cohen, Amélie Guihot, Valérie Guérin, Clémentine Moulin, Marion Caseris, Agnès Carol, Stéphane Bonacorsi, and Guislaine Carcelain
- Subjects
cellular immunity ,ELISpot assay ,intracellular cytokine staining assay ,memory T cells ,paucisymptomatic COVID‐19 ,SARS‐CoV‐2 ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Abstract Introduction Evaluation of different cell‐based assays for the study of adaptive immune responses against SARS‐CoV‐2 is crucial for studying long‐term and vaccine‐induced immunity. Methods Enzyme‐linked immunospot assay (ELISpot) and intracellular cytokine staining (ICS) using peptide pools spanning the spike protein and nucleoprotein of SARS‐CoV‐2 were performed in 25 patients who recovered from paucisymptomatic (n = 19) or severe COVID‐19 (n = 6). Results The proportion of paucisymptomatic patients with detectable SARS‐CoV‐2 T cells was low, as only 44% exhibit a positive T cell response with the ICS and 67% with the ELISpot. The magnitude of SARS‐CoV‐2 T cell responses was low, both with ICS (median at 0.12% among total T cells) and ELISpot (median at 61 SFCs/million peripheral blood mononuclear cells [PBMC]) assays. Moreover, T cell responses in paucisymptomatic patients seemed lower than among patients with severe disease. In the paucisymptomatic patients, the two assays were well correlated with 76% of concordant responses and a Cohen's kappa of 55. Furthermore, in four patients SARS‐CoV‐2 T cells were detected by ELISpot but not with ICS. Short‐term culture could improve the detection of specific T cells. Conclusions In patients who recovered from paucisymptomatic COVID‐19, the proportion of detectable anti‐SARS‐CoV‐2 responses and their magnitude seemed lower than in patients with more severe symptoms. The ELISpot appeared to be more sensitive than the ICS assay. Short‐term culture revealed that paucisymptomatic patients had nonetheless few SARS‐CoV‐2 T cells at a very low rate in peripheral blood. These data indicate that various ex‐vivo assays may lead to different conclusions about the presence or absence of SARS‐CoV‐2 T cell immunity.
- Published
- 2022
- Full Text
- View/download PDF
10. Dynamics of Antibiotic Resistance of Streptococcus pneumoniae in France: A Pediatric Prospective Nasopharyngeal Carriage Study from 2001 to 2022
- Author
-
Alexis Rybak, Corinne Levy, Naïm Ouldali, Stéphane Bonacorsi, Stéphane Béchet, Jean-François Delobbe, Christophe Batard, Isabelle Donikian, Marie Goldrey, Jessica Assouline, Robert Cohen, and Emmanuelle Varon
- Subjects
pneumococcal nasopharyngeal carriage ,children ,acute otitis media ,PCV impact ,third-generation pneumococcal conjugate vaccine ,next-generation pneumococcal conjugate vaccine ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Epidemiological surveillance of nasopharyngeal pneumococcal carriage is important for monitoring serotype distribution and antibiotic resistance, particularly before and after the implementation of pneumococcal conjugate vaccines (PCVs). With a prospective surveillance study in France, we aimed to analyze the dynamics of pneumococcal carriage, antibiotic susceptibility and serotype distribution in children aged 6 to 24 months who had acute otitis media between 2001 and 2022 with a focus on the late PCV13 period from May 2014 to July 2022. Trends were analyzed with segmented linear regression with autoregressive error. For the 17,136 children enrolled, overall pneumococcal carriage was stable during the study. During the late PCV13 period, the five most frequent serotypes were all non-PCV13 serotypes: 15B/C (14.3%), 23B (11.0%), 11A (9.6%), 15A (7.4%) and 35B (6.5%). During the same period, we observed a rebound of penicillin non-susceptibility (+0.15% per month, 95% confidence interval, +0.08 to 0.22, p < 0.001). Five serotypes accounted for 64.4% of the penicillin non-susceptible strains: 11A (17.5%), 35B (14.9%), 15A (13.9%), 15B/C (9.9%) and 19F (8.2%); non-PCV13/PCV15 accounted for
- Published
- 2023
- Full Text
- View/download PDF
11. Shiga Toxin–Associated Hemolytic Uremic Syndrome in Adults, France, 2009–2017
- Author
-
Benoît Travert, Antoine Dossier, Matthieu Jamme, Aurélie Cointe, Yahsou Delmas, Sandrine Malot, Alain Wynckel, Amélie Seguin, Claire Presne, Miguel Hie, Ygal Benhamou, David Ribes, Gabriel Choukroun, Steven Grangé, Alexandre Hertig, Emilie Cornec Le Gall, Lionel Galicier, Eric Daugas, Lila Bouadma, François-Xavier Weill, Elie Azoulay, Fadi Fakhouri, Agnès Veyradier, Stéphane Bonacorsi, Julien Hogan, Véronique Frémeaux-Bacchi, Eric Rondeau, Patricia Mariani-Kurkdjian, and Paul Coppo
- Subjects
hemolytic uremic syndrome ,Shiga toxin ,thrombotic microangiopathy ,Escherichia coli ,E. coli ,bacteria ,Medicine ,Infectious and parasitic diseases ,RC109-216 - Abstract
We conducted a retrospective study on hemolytic uremic syndrome caused by Shiga toxin–producing Escherichia coli (STEC) in 96 adults enrolled in the cohort of the National Reference Center for Thrombotic Microangiopathies network in France during 2009–2017. Most infections were caused by STEC strains not belonging to the O157 or O104 serogroups. Thirty (31.3%) patients had multiple risk factors for thrombotic microangiopathy. In total, 61 (63.5%) patients required dialysis, 50 (52.1%) had a serious neurologic complication, 34 (35.4%) required mechanical ventilation, and 19 (19.8%) died during hospitalization. We used multivariate analysis to determine that the greatest risk factors for death were underlying immunodeficiency (hazard ratio 3.54) and severe neurologic events (hazard ratio 3.40). According to multivariate analysis and propensity score-matching, eculizumab treatment was not associated with survival. We found that underlying conditions, especially immunodeficiency, are strongly associated with decreased survival in adults who have hemolytic uremic syndrome caused by STEC.
- Published
- 2021
- Full Text
- View/download PDF
12. Case Report: Hyperammonemic Encephalopathy Linked to Ureaplasma spp. and/or Mycoplasma hominis Systemic Infection in Patients Treated for Leukemia, an Emergency Not to Be Missed
- Author
-
Manon Delafoy, Juliette Goutines, Aude-Marie Fourmont, André Birgy, Maryline Chomton, Michaël Levy, Jérôme Naudin, Lara Zafrani, Lou Le Mouel, Karima Yakouben, Aurélie Cointe, Marion Caseris, Matthieu Lafaurie, Stéphane Bonacorsi, Françoise Mechinaud, Sabine Pereyre, Nicolas Boissel, and André Baruchel
- Subjects
Ureaplasma spp. ,Mycoplasma spp. ,systemic infection ,hyperammonemic encephalopathy ,immunocompromised patients ,case report ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
BackgroundHyperammonemic encephalopathy caused by Ureaplasma spp. and Mycoplasma hominis infection has been reported in immunocompromised patients undergoing lung transplant, but data are scarce in patients with hematological malignancies.Case PresentationWe describe the cases of 3 female patients aged 11–16 years old, developing initially mild neurologic symptoms, rapidly evolving to coma and associated with very high ammonia levels, while undergoing intensive treatment for acute leukemia (chemotherapy: 2 and hematopoietic stem cell transplant: 1). Brain imaging displayed cerebral edema and/or microbleeding. Electroencephalograms showed diffuse slowing patterns. One patient had moderate renal failure. Extensive liver and metabolic functions were all normal. Ureaplasma spp. and M. hominis were detected by PCR and specific culture in two patients, resulting in prompt initiation of combined antibiotics therapy by fluoroquinolones and macrolides. For these 2 patients, the improvement of the neurological status and ammonia levels were observed within 96 h, without any long-term sequelae. M. hominis was detected post-mortem in vagina, using 16S rRNA PCR for the third patient who died of cerebral edema.ConclusionHyperammonemic encephalopathy linked to Ureaplasma spp. and M. hominis is a rare complication encountered in immunocompromised patients treated for acute leukemia, which can lead to death if unrecognized. Combining our experience with the few published cases (n=4), we observed a strong trend among female patients and very high levels of ammonia, consistently uncontrolled by classical measures (ammonia-scavenging agents and/or continuous kidney replacement therapy). The reversibility of the encephalopathy without sequelae is possible with prompt diagnosis and adequate combined specific antibiotherapy. Any neurological symptoms in an immunocompromised host should lead to the measurement of ammonia levels. If increased, and in the absence of an obvious cause, it should prompt to perform a search for Ureaplasma spp. and M. hominis by PCR as well as an immediate empirical initiation of combined specific antibiotherapy.
- Published
- 2022
- Full Text
- View/download PDF
13. ShiF acts as an auxiliary factor of aerobactin secretion in meningitis Escherichia coli strain S88
- Author
-
Mathieu Genuini, Philippe Bidet, Jean-François Benoist, Dimitri Schlemmer, Chloé Lemaitre, André Birgy, and Stéphane Bonacorsi
- Subjects
Escherichia coli ,Siderophore ,Aerobactin ,ShiF ,Microbiology ,QR1-502 - Abstract
Abstract Background The neonatal meningitis E. coli (NMEC) strain S88 carries a ColV plasmid named pS88 which is involved in meningeal virulence. Transcriptional analysis of pS88 in human serum revealed a strong upregulation of an ORF of unknown function: shiF, which is adjacent to the operon encoding the siderophore aerobactin. The aim of this work is to investigate the role of shiF in aerobactin production in strain S88. Results Study of the prevalence of shiF and aerobactin operon in a collection of 100 extra-intestinal pathogenic E. coli strains (ExPEC) and 50 whole genome-sequenced E. coli strains revealed the colocalization of these two genes for 98% of the aerobactin positive strains. We used Datsenko and Wanner’s method to delete shiF in two S88 mutants. A cross-feeding assay showed that these mutants were able to excrete aerobactin meaning that shiF is dispensable for aerobactin excretion. Our growth assays revealed that the shiF-deleted mutants grew significantly slower than the wild-type strain S88 in iron-depleted medium with a decrease of maximum growth rates of 23 and 28% (p
- Published
- 2019
- Full Text
- View/download PDF
14. Systematic Review on the Correlation of Quantitative PCR Cycle Threshold Values of Gastrointestinal Pathogens With Patient Clinical Presentation and Outcomes
- Author
-
Stéphane Bonacorsi, Benoit Visseaux, Donia Bouzid, Josep Pareja, Sonia N. Rao, Davide Manissero, Glen Hansen, and Jordi Vila
- Subjects
cycle threshold ,pathogen load ,gastrointestinal pathogens ,systematic review ,qPCR ,clinical outcomes ,Medicine (General) ,R5-920 - Abstract
Background: Quantitative (q) polymerase chain reaction (PCR) cycle threshold (Ct) values represent the number of amplification cycles required for a positive PCR result and are a proxy of pathogen quantity in the tested sample. The clinical utility of Ct values remains unclear for gastrointestinal infections.Objectives: This systematic review assesses the global medical literature for associations between Ct values of gastrointestinal pathogens and patient presentation and clinical outcomes.Data Sources: MEDLINE, EMBASE, Cochrane library databases: searched January 14–17, 2020.Study Eligibility Criteria: Studies reporting on the presence or absence of an association between Ct values and clinical outcomes in adult and pediatric populations were included. Animal studies, reviews, meta-analyses, and non-English language studies were excluded.Participants: Humans infected with gastrointestinal pathogens, detected with qPCR.Interventions: Diagnostics assessing Ct values. Extracted data were reported narratively.Results: Thirty-three eligible studies were identified; the most commonly studied pathogens were Clostridioides difficile (n = 15), norovirus (n = 10), and rotavirus (n = 9). Statistically significant associations between low C. difficile Ct values and increased symptom severity or poor outcome were reported in 4/8 (50%) studies, and increased risk of death in 1/2 (50%) studies; no significant associations were found between Ct value and duration of symptoms or length of hospital stay. Among studies of norovirus, 5/7 (71%), mainly genogroup II, reported symptomatic cases with significantly lower median Ct values than controls. Significantly lower rotavirus Ct values were also observed in symptomatic cases vs. controls in 3/7 (43%) studies, and associated with more severe symptoms in 2/2 studies. Contradictory associations were identified for non-C. difficile bacterial and parasitic pathogens.Conclusions: In conclusion, some studies reported clinically useful associations between Ct values and patient or healthcare outcomes; additional, well-designed, large-scale trials are warranted based on these findings.Systematic Review Registration: [PROSPERO], identifier [CRD42020167239].
- Published
- 2021
- Full Text
- View/download PDF
15. Genome sequencing of strains of the most prevalent clonal group of O1:K1:H7 Escherichia coli that causes neonatal meningitis in France
- Author
-
Guillaume Geslain, André Birgy, Sandrine Adiba, Mélanie Magnan, Céline Courroux, Corinne Levy, Robert Cohen, Philippe Bidet, and Stéphane Bonacorsi
- Subjects
Escherichia coli ,Meningitis ,Newborns ,Sequencing data analysis ,Amoeba model ,Microbiology ,QR1-502 - Abstract
Abstract Background To describe the temporal dynamics, molecular characterization, clinical and ex vivo virulence of emerging O1:K1 neonatal meningitis Escherichia coli (NMEC) strains of Sequence Type complex (STc) 95 in France. The national reference center collected NMEC strains and performed whole genome sequencing (WGS) of O1:K1 STc95 NMEC strains for phylogenetic and virulence genes content analysis. Data on the clinical and biological features of patients were also collected. Ex vivo virulence was assessed using the Dictyostelium discoideum amoeba model. Results Among 250 NMEC strains collected between 1998 and 2015, 38 belonged to O1:K1 STc95. This clonal complex was the most frequently collected after 2004, representing up to 25% of NMEC strains in France. Phylogenetic analysis demonstrated that most (74%) belonged to a cluster designated D-1, characterized by the adhesin FimH30. There is no clinical data to suggest that this cluster is more pathogenic than its counterparts, although it is highly predominant and harbors a large repertoire of extraintestinal virulence factors, including a pS88-like plasmid. Ex vivo virulence model showed that this cluster was generally less virulent than STc95 reference strains of O45S88:H7 and O18:H7 serotypes. However, the model showed differences between several subclones, although they harbor the same known virulence determinants. Conclusions The emerging clonal group O1:K1 STc95 of NMEC strains is mainly composed of a cluster with many virulence factors but of only moderate virulence. Whether its emergence is due to its ability to colonize the gut thanks to FimH30 or pS88-like plasmid remains to be determined.
- Published
- 2019
- Full Text
- View/download PDF
16. Emerging Multidrug-Resistant Hybrid Pathotype Shiga Toxin–Producing Escherichia coli O80 and Related Strains of Clonal Complex 165, Europe
- Author
-
Aurélie Cointe, André Birgy, Patricia Mariani-Kurkdjian, Sandrine Liguori, Céline Courroux, Jorge Blanco, Sabine Delannoy, Patrick Fach, Estelle Loukiadis, Philippe Bidet, and Stéphane Bonacorsi
- Subjects
Escherichia coli ,Shiga toxin-producing E. coli ,STEC ,enterohemorrhagic E. coli ,hybrid pathotype ,extra-intestinal virulence ,Medicine ,Infectious and parasitic diseases ,RC109-216 - Abstract
Enterohemorrhagic Escherichia coli serogroup O80, involved in hemolytic uremic syndrome associated with extraintestinal infections, has emerged in France. We obtained circularized sequences of the O80 strain RDEx444, responsible for hemolytic uremic syndrome with bacteremia, and noncircularized sequences of 35 O80 E. coli isolated from humans and animals in Europe with or without Shiga toxin genes. RDEx444 harbored a mosaic plasmid, pR444_A, combining extraintestinal virulence determinants and a multidrug resistance–encoding island. All strains belonged to clonal complex 165, which is distantly related to other major enterohemorrhagic E. coli lineages. All stx-positive strains contained eae-ξ, ehxA, and genes characteristic of pR444_A. Among stx-negative strains, 1 produced extended-spectrum β-lactamase, 1 harbored the colistin-resistance gene mcr1, and 2 possessed genes characteristic of enteropathogenic and pyelonephritis E. coli. Because O80–clonal complex 165 strains can integrate intestinal and extraintestinal virulence factors in combination with diverse drug-resistance genes, they constitute dangerous and versatile multidrug-resistant pathogens.
- Published
- 2018
- Full Text
- View/download PDF
17. Relay oral therapy in febrile urinary tract infections caused by extended spectrum beta-lactamase-producing Enterobacteriaceae in children: A French multicenter study.
- Author
-
Gabriel Lignieres, André Birgy, Camille Jung, Stéphane Bonacorsi, Corinne Levy, François Angoulvant, Emmanuel Grimprel, Marie Aliette Dommergues, Yves Gillet, Irina Craiu, Alexis Rybak, Loic De Pontual, François Dubos, Emmanuel Cixous, Vincent Gajdos, Didier Pinquier, Isabelle Andriantahina, Valérie Soussan-Banini, Emilie Georget, Elise Launay, Olivier Vignaud, Robert Cohen, and Fouad Madhi
- Subjects
Medicine ,Science - Abstract
ObjectivesWe need studies assessing therapeutic options for oral relay in febrile urinary tract infection (FUTI) due to ESBL-producing Enterobacteriaceae (ESBL-E) in children. Amoxicillin-clavulanate/cefixime (AC-cefixime) combination seems to be a suitable option. We sought to describe the risk of recurrence at 1 month after the end of treatment for FUTI due to ESBL-E according to the oral relay therapy used.Materials and methodsWe retrospectively identified children ResultsWe included 199 children who received an oral relay therapy with cotrimoxazole (n = 72, 36.2%), ciprofloxacin (n = 38, 19.1%) or the AC-cefixime combination (n = 89, 44.7%). Nine (4.5%) patients had a recurrence within the first month after the end of treatment, with no difference between the 3 groups of oral relay (p = 0.8): 4 (5.6%) cotrimoxazole, 2 (5.3%) ciprofloxacin and 3 (3.4%) AC-cefixime combination. Phenotype characterization of 249 strains responsible for FUTI due to ESBL-E showed that 97.6% were susceptible to the AC-cefixime combination.ConclusionsThe AC-cefixime combination represents an interesting therapeutic option for oral relay treatment of FUTI due to ESBL-E as the recurrence rate at 1 month after the end of treatment was the same when compared to cotrimoxazole and ciprofloxacin.
- Published
- 2021
- Full Text
- View/download PDF
18. Post–13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children
- Author
-
Corinne Levy, Naim Ouldali, Emmanuelle Varon, Stéphane Béchet, Stéphane Bonacorsi, and Robert Cohen
- Subjects
pneumoccocal serotypes ,children ,PCVs ,pneumococcal conjugate vaccines ,Streptococcus pneumoniae ,vaccines ,Medicine ,Infectious and parasitic diseases ,RC109-216 - Published
- 2021
- Full Text
- View/download PDF
19. Management of Febrile Urinary Tract Infection With or Without Bacteraemia in Children: A French Case-Control Retrospective Study
- Author
-
Caroline Goeller, Marie Desmarest, Aurélie Garraffo, Stéphane Bonacorsi, and Jean Gaschignard
- Subjects
bacteraemia ,Escherichia coli ,pediatric care ,urinary tract infection in infants ,3rd generation cephalosporin ,Pediatrics ,RJ1-570 - Abstract
Background: Febrile urinary tract infections (FUTIs) are common among children, and are associated with a bacteraemia between 4 and 7% of cases. No data is available concerning the management of children with a bacteraemic FUTI.Objectives: To compare the antibiotic treatment (parenteral and total duration) among children with bacteraemic and non-bacteraemic FUTIs, and the mean hospital length of stay (LOS); to describe clinical, microbiological and imaging features of children with bacteraemic and non-bacteraemic FUTIs and observed management modifications when the blood culture was positive.Methods: A retrospective case-control study between 2009 and 2015 at Robert Debré's Pediatric Emergency Department (Paris, France). Children with a bacteraemic FUTI were included and matched for age and sex with two children with a non-bacteraemic FUTI.Results: We included 50 children with a bacteraemic FUTI matched to 100 children with a non-bacterameic FUTI. The mean duration of parenteral antibiotics was longer for bacteraemic children (6.7 vs. 4.0 days, p < 0.001) but this difference was only significant in children > 28 days-old. The mean total duration of antibiotic was similar (11.3 vs. 11.6 days, p = 0.61). The mean LOS was longer for bacteraemic children (5.1 vs. 2.0 days, p < 0.001) but this difference was only significant in children > 28 days-old. A positive blood culture changed the management in 66% of patients. Clinical features at presentation were comparable. Bacteraemic patients had a higher procalcitonin (p = 0.006) and C-reactive protein (p = 0.01), lower mean lymphocyte count (p < 0.001).Conclusions: A bacteraemic FUTI in children induced a longer duration of parenteral antibiotic treatment, a longer hospitalization in children > 28 days-old, and a modification of management for 66% of patients.
- Published
- 2020
- Full Text
- View/download PDF
20. Invasive Streptococcus pyogenes Infections in
- Author
-
Zoé Germont, Philippe Bidet, Céline Plainvert, Stéphane Bonacorsi, Claire Poyart, Valérie Biran, Alice Frérot, Albert Faye, and Romain Basmaci
- Subjects
group A Streptococcus ,invasive infection ,children ,neonatal infection ,prophylaxis ,Pediatrics ,RJ1-570 - Abstract
Few data are available on invasive group A Streptococcus (GAS) infections (IGASIs) in infants. We described initial clinical and laboratory features and outcomes of
- Published
- 2020
- Full Text
- View/download PDF
21. Kingella kingae and Viral Infections
- Author
-
Romain Basmaci, Philippe Bidet, and Stéphane Bonacorsi
- Subjects
Kingella kingae ,virus ,human rhinovirus ,hand foot and mouth disease ,children ,viral infection ,Biology (General) ,QH301-705.5 - Abstract
Kingella kingae (K. kingae) is an oropharyngeal commensal agent of toddlers and the primary cause of osteoarticular infections in 6–23-month-old children. Knowing that the oropharynx of young children is the reservoir and the portal of entry of K. kingae, these results suggested that a viral infection may promote K. kingae infection. In this narrative review, we report the current knowledge of the concomitance between K. kingae and viral infections. This hypothesis was first suggested because some authors described that symptoms of viral infections were frequently concomitant with K. kingae infection. Second, specific viral syndromes, such as hand, foot and mouth disease or stomatitis, have been described in children experiencing a K. kingae infection. Moreover, some clusters of K. kingae infection occurring in daycare centers were preceded by viral outbreaks. Third, the major viruses identified in patients during K. kingae infection were human rhinovirus or coxsackievirus, which both belong to the Picornaviridae family and are known to facilitate bacterial infections. Finally, a temporal association was observed between human rhinovirus circulation and K. kingae infection. Although highly probable, the role of viral infection in the K. kingae pathophysiology remains unclear and is based on case description or temporal association. Molecular studies are needed.
- Published
- 2022
- Full Text
- View/download PDF
22. Emergence of New ST301 Shiga Toxin-Producing Escherichia coli Clones Harboring Extra-Intestinal Virulence Traits in Europe
- Author
-
Aurélie Cointe, Etienne Bizot, Sabine Delannoy, Patrick Fach, Philippe Bidet, André Birgy, François-Xavier Weill, Sophie Lefèvre, Patricia Mariani-Kurkdjian, and Stéphane Bonacorsi
- Subjects
Shiga toxin ,enterohemorrhagic Escherichia coli ,heteropathotypes ,ST301 ,pS88 plasmid ,hemolytic and uremic syndrome ,Medicine - Abstract
O80:H2 enterohemorrhagic Escherichia coli (EHEC) of sequence type ST301 is one of the main serotypes causing European hemolytic and uremic syndrome, but also invasive infections, due to extra-intestinal virulence factors (VFs). Here, we determined whether other such heteropathotypes exist among ST301. EnteroBase was screened for ST301 strains that were included in a general SNP-phylogeny. French strains belonging to a new heteropathotype clone were sequenced. ST, hierarchical clusters (HC), serotype, resistome, and virulome were determined using EnteroBase, the CGE website, and local BLAST. The ST301 general phylogeny shows two groups. Group A (n = 25) is mainly composed of enteropathogenic E. coli, whereas group B (n = 55) includes mostly EHEC. Three serotypes, O186:H2, O45:H2 and O55:H9, share the same virulome as one of the O80:H2 sub-clones from which they derive subsequent O-antigen switches. The O55:H9 clone, mainly present in France (n = 29), as well as in the UK (n = 5) and Germany (n = 1), has a low background of genetic diversity (four HC20), although it has three Stx subtypes, an H-antigen switch, and genes encoding the major extra-intestinal VF yersiniabactin, and extended-spectrum beta-lactamases. Diverse heteropathotype clones genetically close to the O80:H2 clone are present among the ST301, requiring close European monitoring, especially the virulent O55:H9 clone.
- Published
- 2021
- Full Text
- View/download PDF
23. Bacterial causes of otitis media with spontaneous perforation of the tympanic membrane in the era of 13 valent pneumococcal conjugate vaccine.
- Author
-
Corinne Levy, Emmanuelle Varon, Naim Ouldali, Alain Wollner, Franck Thollot, François Corrard, Andreas Werner, Stéphane Béchet, Stéphane Bonacorsi, and Robert Cohen
- Subjects
Medicine ,Science - Abstract
After pneumococcal conjugate vaccine (PCV) implementation, the number of acute otitis media (AOM) episodes has decreased, but AOM still remains among the most common diagnoses in childhood. From 2% to 17% of cases of AOM feature spontaneous perforation of the tympanic membrane (SPTM). The aim of this study was to describe the bacteriological causes of SPTM 5 to 8 years years after PCV13 implementation, in 2010. From 2015 to 2018, children with SPTM were prospectively enrolled by 41 pediatricians. Middle ear fluid was obtained by sampling spontaneous discharge. Among the 470 children with SPTM (median age 20.8 months), no otopathogen was isolated for 251 (53.4% [95% CI 48.8%;58.0%]): 47.1% of infants and toddlers, 68.3% older children (p
- Published
- 2019
- Full Text
- View/download PDF
24. Enterohemorrhagic Escherichia coli Hybrid Pathotype O80:H2 as a New Therapeutic Challenge
- Author
-
Nurcan Soysal, Patricia Mariani-Kurkdjian, Yasmine Smail, Sandrine Liguori, Malika Gouali, Estelle Loukiadis, Patrick Fach, Mathias Bruyand, Jorge Blanco, Philippe Bidet, and Stéphane Bonacorsi
- Subjects
enterohemorrhagic Escherichia coli ,Shiga toxin ,hemolytic uremic syndrome ,extraintestinal virulence factors ,pS88 plasmid ,bacteremia ,Medicine ,Infectious and parasitic diseases ,RC109-216 - Abstract
We describe the epidemiology, clinical features, and molecular characterization of enterohemorrhagic Escherichia coli (EHEC) infections caused by the singular hybrid pathotype O80:H2, and we examine the influence of antibiotics on Shiga toxin production. In France, during 2005–2014, a total of 54 patients were infected with EHEC O80:H2; 91% had hemolytic uremic syndrome. Two patients had invasive infections, and 2 died. All strains carried stx2 (variants stx2a, 2c, or 2d); the rare intimin gene (eae-ξ); and at least 4 genes characteristic of pS88, a plasmid associated with extraintestinal virulence. Similar strains were found in Spain. All isolates belonged to the same clonal group. At subinhibitory concentrations, azithromycin decreased Shiga toxin production significantly, ciprofloxacin increased it substantially, and ceftriaxone had no major effect. Antibiotic combinations that included azithromycin also were tested. EHEC O80:H2, which can induce hemolytic uremic syndrome complicated by bacteremia, is emerging in France. However, azithromycin might effectively combat these infections.
- Published
- 2016
- Full Text
- View/download PDF
25. Emerging Shiga-toxin-producing Escherichia coli serogroup O80 associated hemolytic and uremic syndrome in France, 2013-2016: Differences with other serogroups.
- Author
-
Brecht Ingelbeen, Mathias Bruyand, Patricia Mariani-Kurkjian, Simon Le Hello, Kostas Danis, Cécile Sommen, Stéphane Bonacorsi, and Henriette de Valk
- Subjects
Medicine ,Science - Abstract
To generate hypotheses on possible sources of Shiga toxin-producing Escherichia coli (STEC) serogroup O80 associated hemolytic-uremic syndrome (HUS), we explored differences in factors associated with STEC O80 associated HUS, compared with STEC O157 or STEC of other serogroups, in France during 2013-16. STEC was isolated from 153/521 (30%) reported HUS cases: 45 serogroup O80, 46 O157 and 62 other serogroups. Median ages were 1.1 years, 4.0 years and 1.8 years, respectively. O80 infected patients were less likely to report ground beef consumption (aOR [adjusted Odds Ratio] 0.14 95% CI [Confidence Interval] 0.02-0.80) or previous contact with a person with diarrhea or HUS (aOR 0.13 95%CI 0.02-0.78) than patients infected with STEC O157. They were also less likely to report previous contact with a person presenting with diarrhea/HUS than patients infected with other serogroups (aOR 0.13 95%CI 0.02-0.78). STEC O80 spread all over France among young children less exposed to known risk factors of O157 or other STEC infections, suggesting the existence of different reservoirs and transmission patterns.
- Published
- 2018
- Full Text
- View/download PDF
26. Febrile urinary-tract infection due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in children: A French prospective multicenter study.
- Author
-
Fouad Madhi, Camille Jung, Sandra Timsit, Corinne Levy, Sandra Biscardi, Mathie Lorrot, Emmanuel Grimprel, Laure Hees, Irina Craiu, Aurelien Galerne, François Dubos, Emmanuel Cixous, Véronique Hentgen, Stéphane Béchet, Urinary-tract Infection due to Extended-Spectrum Beta-lactamase–producing Enterobacteriaceae in Children Group, Stéphane Bonacorsi, and Robert Cohen
- Subjects
Medicine ,Science - Abstract
To assess the management of febrile urinary-tract infection (FUTIs) due to extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) in children, the Pediatric Infectious Diseases Group of the French Pediatric Society set up an active surveillance network in pediatric centers across France in 2014.We prospectively analysed data from 2014 to 2016 for all children < 18 years old who received antibiotic treatment for FUTI due to ESBL-E in 24 pediatric centers. Baseline demographic, clinical features, microbiological data and antimicrobials prescribed were collected.301 children were enrolled in this study. The median age was 1 year (IQR 0.02-17.9) and 44.5% were male. These infections occurred in children with history of UTIs (27.3%) and urinary malformations (32.6%). Recent antibiotic use was the main associated factor for FUTIs due to ESBL-E, followed by a previous hospitalization and travel history. Before drug susceptibility testing (DST), third-generation cephalosporins (3GC) PO/IV were the most-prescribed antibiotics (75.5%). Only 13% and 24% of children received amikacine alone for empirical or definitive therapy, respectively, whereas 88.7% of children had isolates susceptible to amikacin. In all, 23.2% of children received carbapenems in empirical and/or definitive therapy. Cotrimoxazole (24.5%), ciprofloxacin (15.6%) and non-orthodox clavulanate-cefixime combination (31.3%) were the most frequently prescribed oral options after obtaining the DST. The time to apyrexia and length of hospital stay did not differ with or without effective empirical therapy.We believe that amikacin should increasingly take on a key role in the choice of definitive therapy of FUTI due to ESBL-E in children by avoiding the use of carbapenems.
- Published
- 2018
- Full Text
- View/download PDF
27. First case of pregnant women bacteraemia and probable early-onset neonatal infection due to Aerococcus urinae
- Author
-
Christelle Jost, Bénedicte Breton, Valérie Biran, Suonavy Khung, Sarah Chekroune, and Stéphane Bonacorsi
- Subjects
Aerococcus urinae ,pregnancy ,bacteraemia ,Infectious and parasitic diseases ,RC109-216 - Published
- 2015
- Full Text
- View/download PDF
28. CTX-M-27–Producing Escherichia coli of Sequence Type 131 and Clade C1-M27, France
- Author
-
André Birgy, Philippe Bidet, Corinne Levy, Elsa Sobral, Robert Cohen, and Stéphane Bonacorsi
- Subjects
E. coli ,ST131 ,C1-M27 clade ,CTX-M-27 ,ESBL ,fimH30 ,Medicine ,Infectious and parasitic diseases ,RC109-216 - Published
- 2017
- Full Text
- View/download PDF
29. A conserved virulence plasmidic region contributes to the virulence of the multiresistant Escherichia coli meningitis strain S286 belonging to phylogenetic group C.
- Author
-
Chloé Lemaître, Farah Mahjoub-Messai, Damien Dupont, Valérie Caro, Laure Diancourt, Edouard Bingen, Philippe Bidet, and Stéphane Bonacorsi
- Subjects
Medicine ,Science - Abstract
Recent isolation of the non-K1 Escherichia coli neonatal meningitis strain S286, belonging to phylogroup C, which is closely related to major group B1, and producing an extended-spectrum beta-lactamase, encouraged us to seek the genetic determinants responsible for its virulence. We show that S286 belongs to the sequence O type ST23O78 and harbors 4 large plasmids. The largest one, pS286colV (~120 kb), not related to resistance, contains genes characteristic of a Conserved Virulence Plasmidic (CVP) region initially identified in B2 extra-intestinal avian pathogenic E. coli (APEC) strains and in the B2 neonatal meningitis E. coli strain S88. The sequence of this CVP region has a strong homology (98%) with that of the recently sequenced plasmid pChi7122-1 of the O78 APEC strain Chi7122. A CVP plasmid-cured variant of S286 was less virulent than the wild type strain in a neonatal rat sepsis model with a significant lower level of bacteremia at 24 h (4.1 ± 1.41 versus 2.60 ± 0.16 log CFU/ml, p = 0.001) and mortality. However, the mortality in the model of adult mice was comparable between wild type and variant indicating that pS286colV is not sufficient by itself to fully explain the virulence of S286. Gene expression analysis of pS286colV in iron depleted environment was very close to that of pS88, suggesting that genes of CVP region may be expressed similarly in two very different genetic backgrounds (group C versus group B2). Screening a collection of 178 human A/B1 extraintestinal pathogenic E. coli (ExPEC) strains revealed that the CVP region is highly prevalent (23%) and MLST analysis indicated that these CVP positive strains belong to several clusters and mostly to phylogroup C. The virulence of S286 is explained in part by the presence of CVP region and this region has spread in different clusters of human A/B1 ExPEC, especially in group C.
- Published
- 2013
- Full Text
- View/download PDF
30. Multilocus sequence typing and rtxA toxin gene sequencing analysis of Kingella kingae isolates demonstrates genetic diversity and international clones.
- Author
-
Romain Basmaci, Pablo Yagupsky, Brice Ilharreborde, Kathleen Guyot, Nurith Porat, Marilyn Chomton, Jean-Michel Thiberge, Keyvan Mazda, Edouard Bingen, Stéphane Bonacorsi, and Philippe Bidet
- Subjects
Medicine ,Science - Abstract
BACKGROUND: Kingella kingae, a normal component of the upper respiratory flora, is being increasingly recognized as an important invasive pathogen in young children. Genetic diversity of this species has not been studied. METHODS: We analyzed 103 strains from different countries and clinical origins by a new multilocus sequence-typing (MLST) schema. Putative virulence gene rtxA, encoding an RTX toxin, was also sequenced, and experimental virulence of representative strains was assessed in a juvenile-rat model. RESULTS: Thirty-six sequence-types (ST) and nine ST-complexes (STc) were detected. The main STc 6, 14 and 23 comprised 23, 17 and 20 strains respectively, and were internationally distributed. rtxA sequencing results were mostly congruent with MLST, and showed horizontal transfer events. Of interest, all members of the distantly related ST-6 (n = 22) and ST-5 (n = 4) harboured a 33 bp duplication or triplication in their rtxA sequence, suggesting that this genetic trait arose through selective advantage. The animal model revealed significant differences in virulence among strains of the species. CONCLUSION: MLST analysis reveals international spread of ST-complexes and will help to decipher acquisition and evolution of virulence traits and diversity of pathogenicity among K. kingae strains, for which an experimental animal model is now available.
- Published
- 2012
- Full Text
- View/download PDF
31. Organised genome dynamics in the Escherichia coli species results in highly diverse adaptive paths.
- Author
-
Marie Touchon, Claire Hoede, Olivier Tenaillon, Valérie Barbe, Simon Baeriswyl, Philippe Bidet, Edouard Bingen, Stéphane Bonacorsi, Christiane Bouchier, Odile Bouvet, Alexandra Calteau, Hélène Chiapello, Olivier Clermont, Stéphane Cruveiller, Antoine Danchin, Médéric Diard, Carole Dossat, Meriem El Karoui, Eric Frapy, Louis Garry, Jean Marc Ghigo, Anne Marie Gilles, James Johnson, Chantal Le Bouguénec, Mathilde Lescat, Sophie Mangenot, Vanessa Martinez-Jéhanne, Ivan Matic, Xavier Nassif, Sophie Oztas, Marie Agnès Petit, Christophe Pichon, Zoé Rouy, Claude Saint Ruf, Dominique Schneider, Jérôme Tourret, Benoit Vacherie, David Vallenet, Claudine Médigue, Eduardo P C Rocha, and Erick Denamur
- Subjects
Genetics ,QH426-470 - Abstract
The Escherichia coli species represents one of the best-studied model organisms, but also encompasses a variety of commensal and pathogenic strains that diversify by high rates of genetic change. We uniformly (re-) annotated the genomes of 20 commensal and pathogenic E. coli strains and one strain of E. fergusonii (the closest E. coli related species), including seven that we sequenced to completion. Within the approximately 18,000 families of orthologous genes, we found approximately 2,000 common to all strains. Although recombination rates are much higher than mutation rates, we show, both theoretically and using phylogenetic inference, that this does not obscure the phylogenetic signal, which places the B2 phylogenetic group and one group D strain at the basal position. Based on this phylogeny, we inferred past evolutionary events of gain and loss of genes, identifying functional classes under opposite selection pressures. We found an important adaptive role for metabolism diversification within group B2 and Shigella strains, but identified few or no extraintestinal virulence-specific genes, which could render difficult the development of a vaccine against extraintestinal infections. Genome flux in E. coli is confined to a small number of conserved positions in the chromosome, which most often are not associated with integrases or tRNA genes. Core genes flanking some of these regions show higher rates of recombination, suggesting that a gene, once acquired by a strain, spreads within the species by homologous recombination at the flanking genes. Finally, the genome's long-scale structure of recombination indicates lower recombination rates, but not higher mutation rates, at the terminus of replication. The ensuing effect of background selection and biased gene conversion may thus explain why this region is A+T-rich and shows high sequence divergence but low sequence polymorphism. Overall, despite a very high gene flow, genes co-exist in an organised genome.
- Published
- 2009
- Full Text
- View/download PDF
32. CARD15/NOD2 is required for Peyer's patches homeostasis in mice.
- Author
-
Frédérick Barreau, Ulrich Meinzer, Fabrice Chareyre, Dominique Berrebi, Michiko Niwa-Kawakita, Monique Dussaillant, Benoit Foligne, Vincent Ollendorff, Martine Heyman, Stéphane Bonacorsi, Thecla Lesuffleur, Ghislaine Sterkers, Marco Giovannini, and Jean-Pierre Hugot
- Subjects
Medicine ,Science - Abstract
BackgroundCARD15/NOD2 mutations are associated with susceptibility to Crohn's Disease (CD) and Graft Versus Host Disease (GVHD). CD and GVHD are suspected to be related with the dysfunction of Peyer's patches (PP) and isolated lymphoid follicles (LFs). Using a new mouse model invalidated for Card15/Nod2 (KO), we thus analysed the impact of the gene in these lymphoid formations together with the development of experimental colitis.Methodology/principal findingsAt weeks 4, 12 and 52, the numbers of PPs and LFs were higher in KO mice while no difference was observed at birth. At weeks 4 and 12, the size and cellular composition of PPs were analysed by flow cytometry and immunohistochemistry. PPs of KO mice were larger with an increased proportion of M cells and CD4(+) T-cells. KO mice were also characterised by higher concentrations of TNFalpha, IFNgamma, IL12 and IL4 measured by ELISA. In contrast, little differences were found in the PP-free ileum and the spleen of KO mice. By using chamber experiments, we found that this PP phenotype is associated with an increased of both paracellular permeability and yeast/bacterial translocation. Finally, KO mice were more susceptible to the colitis induced by TNBS.ConclusionsCard15/Nod2 deficiency induces an abnormal development and function of the PPs characterised by an exaggerated immune response and an increased permeability. These observations provide a comprehensive link between the molecular defect and the Human CARD15/NOD2 associated disorders: CD and GVHD.
- Published
- 2007
- Full Text
- View/download PDF
33. Factors linked to Staphylococcus aureus healthcare-associated infections among pediatric intensive care unit colonized patients
- Author
-
Perrine See, Stéphane Bonacorsi, Artemis Toumazi, Catherine Doit, Jérôme Naudin, Maryline Chomton, Fleur Le Bourgeois, Marion Caseris, Patricia Mariani-Kurkdjian, Géraldine Poncelet, Guillaume Geslain, Stéphane Dauger, and Michael Levy
- Subjects
Pediatrics, Perinatology and Child Health - Published
- 2023
34. Dynamics of Antibiotic Resistance of Streptococcus pneumoniae in France: A Pediatric Prospective Nasopharyngeal Carriage Study from 2001 to 2022
- Author
-
Varon, Alexis Rybak, Corinne Levy, Naïm Ouldali, Stéphane Bonacorsi, Stéphane Béchet, Jean-François Delobbe, Christophe Batard, Isabelle Donikian, Marie Goldrey, Jessica Assouline, Robert Cohen, and Emmanuelle
- Subjects
pneumococcal nasopharyngeal carriage ,children ,acute otitis media ,PCV impact ,third-generation pneumococcal conjugate vaccine ,next-generation pneumococcal conjugate vaccine - Abstract
Epidemiological surveillance of nasopharyngeal pneumococcal carriage is important for monitoring serotype distribution and antibiotic resistance, particularly before and after the implementation of pneumococcal conjugate vaccines (PCVs). With a prospective surveillance study in France, we aimed to analyze the dynamics of pneumococcal carriage, antibiotic susceptibility and serotype distribution in children aged 6 to 24 months who had acute otitis media between 2001 and 2022 with a focus on the late PCV13 period from May 2014 to July 2022. Trends were analyzed with segmented linear regression with autoregressive error. For the 17,136 children enrolled, overall pneumococcal carriage was stable during the study. During the late PCV13 period, the five most frequent serotypes were all non-PCV13 serotypes: 15B/C (14.3%), 23B (11.0%), 11A (9.6%), 15A (7.4%) and 35B (6.5%). During the same period, we observed a rebound of penicillin non-susceptibility (+0.15% per month, 95% confidence interval, +0.08 to 0.22, p < 0.001). Five serotypes accounted for 64.4% of the penicillin non-susceptible strains: 11A (17.5%), 35B (14.9%), 15A (13.9%), 15B/C (9.9%) and 19F (8.2%); non-PCV13/PCV15 accounted for
- Published
- 2023
- Full Text
- View/download PDF
35. Does the use of intrawound povidone-iodine irrigation and local vancomycin powder impact surgical site infection rate in adolescent idiopathic scoliosis surgery?
- Author
-
Cindy Mallet, Victor Meissburger, Marion Caseris, Adèle Happiette, Jason Chinnappa, Stéphane Bonacorsi, Anne-Laure Simon, and Brice Ilharreborde
- Subjects
Adult ,Adolescent ,Antibiotic Prophylaxis ,Anti-Bacterial Agents ,Scoliosis ,Vancomycin ,Humans ,Surgical Wound Infection ,Orthopedics and Sports Medicine ,Surgery ,Kyphosis ,Powders ,Povidone-Iodine ,Retrospective Studies - Abstract
Surgical site infection (SSI) is a major complication after adolescent idiopathic scoliosis (AIS) surgery, with an incidence ranging from 0.5 to 7%. Intraoperative wound decontamination with povidone-iodine (PVP-I) irrigation and/or vancomycin powder in adult spinal surgery has gained attention in the literature with controversial results. The aim of this study was to investigate the impact of using intrawound PVP-I irrigation and local vancomycin powder (LVP) on the incidence of early SSI in AIS surgery.All AIS patients who underwent posterior spinal fusion between October 2016 and December 2019 were retrospectively reviewed. The incidence of early SSI was reported and compared between 2 groups defined by the treating spinal surgeons' preferences: group 1-intrawound irrigation with 2L of PVP-I and application of 3 g LVP before closure and control group 2-patients that did not receive either of these measures.Nine early cases of SSI (2.9%) were reported among the 307 AIS posterior spinal fusion patients. Incidence of SSI in group 1 (2/178 = 1.1%) was significantly lower than in group 2 (7/129 = 5.4%; p = 0.04). There were no adverse reactions to the use of PVP-I and LVP in our study. At latest follow-up, rate of surgical revision for mechanical failure with pseudarthrosis was significantly lower in group 1 (2/178 = 1.1%) than in group 2 (9/129 = 7.0%; p = 0.01).Intraoperative use of intrawound PVP-I irrigation and vancomycin powder is associated with a significant reduction of early SSI after AIS spine surgery.Retrospective study.
- Published
- 2022
36. Early-onset neonatal sepsis in the Paris area: a population-based surveillance study from 2019 to 2021
- Author
-
Paola, Sikias, Valérie, Biran, Laurence, Foix-L'Hélias, Céline, Plainvert, Pascal, Boileau, Stéphane, Bonacorsi, and C, Crenn-Hebert
- Subjects
Pediatrics, Perinatology and Child Health ,Obstetrics and Gynecology ,General Medicine - Abstract
BackgroundEarly-onset neonatal sepsis (EOS) is a rare condition but an important cause of severe morbidity and mortality in neonates.MethodsThis is a prospective observational study in neonates born at ≥34 weeks of gestation (WG). The primary endpoint was EOS, defined by isolation of pathogenic species from blood culture and/or cerebrospinal fluid culture within 72 hours after birth. Data on EOS were collected exhaustively from all maternity wards in Paris area (April 2019–March 2021).Results108 EOS were recorded (annual incidence, 0.32 per 1000 live births; 95% CI 0.26 to 0.38). In term infants, the most frequent pathogens were group BStreptococcus(GBS) (n=47) andEscherichia coli(n=20); in late preterm infants, the most frequent pathogens wereE. coli(n=15) and GBS (n=7). Fifteen meningitis cases were diagnosed. FiveE. colistrains (14%) were resistant to both amoxicillin and gentamicin, which is an empiric treatment for EOS. Of the 54 infants with GBS infections, 35 were born from mothers with negative GBS prepartum screening test and 8 from mothers with no screening. Two deaths were reported, both in term infants (Proteus mirabilisandE. coli).ConclusionIn neonates ≥34 WG born in the Paris area, GBS was twice as frequent asE. coliin term infants. EOS was six times more frequent in late preterm than in term infants and was due toE. coliin 60% of cases. Prevention of GBS EOS and empiric antibiotic treatment of EOS could be improved.
- Published
- 2022
37. Reassessing the Performance of the 'Step-By-Step' Approach to Febrile Infants 90 Days of Age and Younger in the Context of the COVID-19 Pandemic: A Multicentric Retrospective Study
- Author
-
Alexis, Rybak, Camille, Aupiais, Marie, Cotillon, Romain, Basmaci, Loïc, de Pontual, Stéphane, Bonacorsi, Patricia, Mariani, Luce, Landraud, Ségolène, Brichler, Isabelle, Poilane, Naïm, Ouldali, and Luigi, Titomanlio
- Subjects
Microbiology (medical) ,Fever ,COVID-19 ,Infant ,Bacterial Infections ,Infectious Diseases ,Urinary Tract Infections ,Pediatrics, Perinatology and Child Health ,Humans ,Prospective Studies ,Child ,Pandemics ,Procalcitonin ,Retrospective Studies - Abstract
Infants with COVID-19 can often present with fever without source, which is a challenging situation in infants90 days old. The "step-by-step" algorithm has been proposed to identify children at high risk of bacterial infection. In the context of the COVID-19 pandemic, we aimed to reassess the diagnostic performance of this algorithm.We performed a multicentric retrospective study in 3 French pediatric emergency departments between 2018 and 2020. We applied the "step-by-step" algorithm to 4 clinical entities: COVID-19, febrile urinary tract infections (FUTI), invasive bacterial infection (IBI), and enterovirus infections. The main outcome was the proportion of infants classified at high risk (ill-appearing, ≤21 days old, with leukocyturia or procalcitonin level ≥0.5 ng/mL).Among the 199 infants included, 40 had isolated COVID-19, 25 had IBI, 60 had FUTI, and 74 had enterovirus infection. All but 1 infant with bacterial infection were classified at high risk (96% for IBI and 100% for FUTI) as well as 95% with enterovirus and 82% with COVID-19. Infants with COVID-19 were classified at high risk because an ill-appearance (72%), an age ≤21 days (27%), or leukocyturia (19%). All these infants had procalcitonin values0.5 ng/mL and only 1 had C-reactive protein level20 mg/L.The "step-by-step" algorithm remains effective to identify infants with bacterial infection but misclassifies most infants with COVID-19 as at high risk of bacterial infection leading to unnecessary cares. An updated algorithm based adding viral testing may be needed to discriminate fever related to isolated COVID-19 in infants90 days old.
- Published
- 2022
38. Meningitis caused by extended-spectrum β-lactamase-producing Escherichia coli in infants in France: a case series
- Author
-
Gabriel Lignieres, Alexis Rybak, Corinne Levy, André Birgy, Stéphane Bechet, Stéphane Bonacorsi, Robert Cohen, and Fouad Madhi
- Subjects
Microbiology (medical) ,Infectious Diseases ,Immunology ,Immunology and Allergy ,Microbiology - Abstract
Objectives We report the first case series focusing on clinical and biological characteristics of meningitis caused by ESBL-producing Escherichia coli in infants. Methods Between 2001 and 2020, data on all cases of E. coli meningitis were prospectively collected from a network of 259 paediatric wards and 168 microbiology laboratories in France. We analysed the clinical and biological characteristics, short-term complications and long-term sequelae of ESBL-producing E. coli meningitis cases in patients Results In total, 548 cases of E. coli paediatric meningitis were reported. ESBL-producing E. coli represented 12 (2.2%) cases. We included 10 patients aged Conclusions Meropenem seems to be the treatment of choice for ESBL-producing E. coli meningitis in children and needs to be given as early as possible (
- Published
- 2023
39. Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview
- Author
-
Claire Amaris Hobson, Gautier Pierrat, Olivier Tenaillon, Stéphane Bonacorsi, Béatrice Bercot, Ella Jaouen, Hervé Jacquier, and André Birgy
- Subjects
Pharmacology ,Microbial Sensitivity Tests ,Ceftazidime ,beta-Lactamases ,Anti-Bacterial Agents ,Klebsiella Infections ,Drug Combinations ,Klebsiella pneumoniae ,Infectious Diseases ,Bacterial Proteins ,Carbapenems ,Drug Resistance, Multiple, Bacterial ,Humans ,Pharmacology (medical) ,Minireview ,beta-Lactamase Inhibitors ,Azabicyclo Compounds - Abstract
First variants of the Klebsiella pneumoniae carbapenemase (KPC), KPC-2 and KPC-3, have encountered a worldwide success, particularly in K. pneumoniae isolates. These beta-lactamases conferred resistance to most beta-lactams including carbapenems but remained susceptible to new beta-lactam/beta-lactamase inhibitors, such as ceftazidime-avibactam. After the marketing of ceftazidime-avibactam, numerous variants of KPC resistant to this association have been described among isolates recovered from clinical samples or derived from experimental studies. In KPC variants resistant to ceftazidime-avibactam, point mutations, insertions and/or deletions have been described in various hot spots. Deciphering the impact of these mutations is crucial, not only from a therapeutic point of view, but also to follow the evolution in time and space of KPC variants resistant to ceftazidime-avibactam. In this review, we describe the mutational landscape of the KPC beta-lactamase toward ceftazidime-avibactam resistance based on a multidisciplinary approach including epidemiology, microbiology, enzymology, and thermodynamics. We show that resistance is associated with three hot spots, with a high representation of insertions and deletions compared with other class A beta-lactamases. Moreover, extension of resistance to ceftazidime-avibactam is associated with a trade-off in the resistance to other beta-lactams and a decrease in enzyme stability. Nevertheless, the high natural stability of KPC could underlay the propensity of this enzyme to acquire in vivo mutations conferring resistance to ceftazidime-avibactam (CAZavi), particularly via insertions and deletions.
- Published
- 2023
40. Clinical impact of a gastrointestinal PCR panel in children with infectious diarrhoea
- Author
-
Jeanne Truong, Aurélie Cointe, Enora Le Roux, Philippe Bidet, Morgane Michel, Julien Boize, Patricia Mariani-Kurkdjian, Marion Caseris, Claire Amaris Hobson, Marie Desmarest, Luigi Titomanlio, Albert Faye, and Stéphane Bonacorsi
- Subjects
Diarrhea ,Feces ,Pediatrics, Perinatology and Child Health ,Escherichia coli ,Humans ,Child ,Multiplex Polymerase Chain Reaction ,Anti-Bacterial Agents ,Gastroenteritis - Abstract
ObjectivesMultiplex gastrointestinal PCR (GI-PCR) allows fast and simultaneous detection of 22 enteric pathogens (including Campylobacter, Salmonella, Shigella/enteroinvasive Escherichia coli (EIEC), among other bacteria, parasites and viruses). However, its impact on the management of children with infectious diarrhoea remains unknown.Patients/DesignAll children eligible for stool culture from May to October 2018 were prospectively included in a monocentric study at Robert-Debré University-Hospital.InterventionA GI-PCR (BioFire FilmArray) was performed on each stool sample.Main measuresData on the children’s healthcare management before and after GI-PCR results were collected. Stool culture results were also reported.Results172 children were included. The main criteria for performing stool analysis were mucous/bloody diarrhoea and/or traveller’s diarrhoea (n=130). GI-PCR’s were positive for 120 patients (70%). The main pathogens were enteroaggregative E. coli (n=39; 23%), enteropathogenic E. coli (n=34; 20%), Shigella/EIEC (n=27; 16%) and Campylobacter (n=21; 12%). Compared with stool cultures, GI-PCR enabled the detection of 21 vs 19 Campylobacter, 12 vs 10 Salmonella, 27 Shigella/EIEC vs 13 Shigella, 2 vs 2 Yersinia enterocolitica, 1 vs 1 Plesiomonas shigelloides, respectively. Considering the GI-PCR results and before stool culture results, the medical management was revised for 40 patients (23%): 28 initiations, 2 changes and 1 discontinuation of antibiotics, 1 hospitalisation, 2 specific room isolations related to Clostridioides difficile infections, 4 additional test prescriptions and 2 test cancellations.ConclusionThe GI-PCR’s results impacted the medical management of gastroenteritis for almostone-fourth of the children, and especially the prescription of appropriate antibiotic treatment before stool culture results.
- Published
- 2021
41. Unprecedentedly high rates of Group A Streptococcus nasopharyngeal carriage in infants and toddlers in France, 2022–2023
- Author
-
Robert Cohen, Philippe Bidet, Emmanuelle Varon, Stéphane Béchet, Jérémie F. Cohen, Stéphane Bonacorsi, and Corinne Levy
- Subjects
Infectious Diseases - Published
- 2023
42. Association of Nonpharmaceutical Interventions During the COVID-19 Pandemic With Invasive Pneumococcal Disease, Pneumococcal Carriage, and Respiratory Viral Infections Among Children in France
- Author
-
Alexis Rybak, Corinne Levy, François Angoulvant, Anne Auvrignon, Piotr Gembara, Kostas Danis, Sophie Vaux, Daniel Levy-Bruhl, Sylvie van der Werf, Stéphane Béchet, Stéphane Bonacorsi, Zein Assad, Andréa Lazzati, Morgane Michel, Florentia Kaguelidou, Albert Faye, Robert Cohen, Emmanuelle Varon, Naïm Ouldali, Association Clinique et Thérapeutique Infantile du Val de Marne (ACTIV), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Health data- and model- driven Knowledge Acquisition (HeKA), Inria de Paris, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité)-École Pratique des Hautes Études (EPHE), Association Française de Pédiatrie Ambulatoire (AFPA), Santé publique France - French National Public Health Agency [Saint-Maurice, France], Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur), Institut Pasteur [Paris] (IP), AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Epidémiologie Clinique et Evaluation Economique Appliquées aux Populations Vulnérables (ECEVE (U1123 / UMR_S_1123)), Institut National de la Santé et de la Recherche Médicale (INSERM)-AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Cité (UPCité), Centre Hospitalier Intercommunal de Créteil (CHIC), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre Hospitalier Universitaire Sainte-Justine and Pediatrics, Université de Montréal (UdeM), and This work was supported by funding from Pfizer (via ACTIV) for the pneumococcal carriage study, funding from the French Institute for Public Health Surveillance (via the National Reference Center for Pneumococci) for the invasive pneumococcal disease study, and a 2021-2023 fellowship award from the European Society of Pediatric Infectious Diseases (Dr Ouldali).
- Subjects
Male ,MESH: Humans ,MESH: Influenza, Human ,[SDV]Life Sciences [q-bio] ,COVID-19 ,Infant ,General Medicine ,MESH: Infant ,Pneumococcal Infections ,MESH: Male ,Cohort Studies ,MESH: Viruses ,MESH: Influenza Vaccines ,Streptococcus pneumoniae ,Influenza Vaccines ,MESH: Child ,Influenza, Human ,Viruses ,Humans ,MESH: COVID-19 ,MESH: Pneumococcal Infections ,Child ,Pandemics ,MESH: Cohort Studies ,MESH: Streptococcus pneumoniae - Abstract
International audience; Key PointsQuestion Was the implementation of nonpharmaceutical interventions (NPIs) during the COVID-19 pandemic associated with changes in the incidence of invasive pneumococcal disease (IPD) and associated pneumococcal carriage and respiratory viral infections (RSVs) in children in France?Findings In this cohort study using interrupted time series analysis of data from multiple national surveillance systems involving 11 944 children, the incidence of pediatric IPD decreased after implementation of NPIs during the COVID-19 pandemic. This decrease was associated with decreases in influenza and RSV cases, but the pneumococcal carriage rate remained stable.Meaning These results suggest that the established association between pneumococcal carriage and IPD was modified after viral epidemiological changes associated with NPIs, suggesting that interventions targeting respiratory viruses may help prevent a large proportion of pediatric IPD cases.AbstractImportance An association between pneumococcal nasopharyngeal carriage and invasive pneumococcal disease (IPD) has been previously established. However, it is unclear whether the decrease in IPD incidence observed after implementation of nonpharmaceutical interventions (NPIs) during the COVID-19 pandemic was associated with concomitant changes in pneumococcal carriage and respiratory viral infections.Objective To assess changes in IPD incidence after the implementation of NPIs during the COVID-19 pandemic and examine their temporal association with changes in pneumococcal carriage rate and respiratory viral infections (specifically respiratory syncytial virus [RSV] and influenza cases) among children in France.Design, Setting, and Participants This cohort study used interrupted time series analysis of data from ambulatory and hospital-based national continuous surveillance systems of pneumococcal carriage, RSV and influenza-related diseases, and IPD between January 1, 2007, and March 31, 2021. Participants included 11 944 children younger than 15 years in France.Exposures Implementation of NPIs during the COVID-19 pandemic.Main Outcomes and Measures The estimated fraction of IPD change after implementation of NPIs and the association of this change with concomitant changes in pneumococcal carriage rate and RSV and influenza cases among children younger than 15 years. The estimated fraction of change was analyzed using a quasi-Poisson regression model.Results During the study period, 5113 children (median [IQR] age, 1.0 [0.6-4.0] years; 2959 boys [57.9%]) had IPD, and 6831 healthy children (median [IQR] age, 1.5 [0.9-3.9] years; 3534 boys [51.7%]) received a swab test. Data on race and ethnicity were not collected. After NPI implementation, IPD incidence decreased by 63% (95% CI, −82% to −43%; P
- Published
- 2022
43. Multicentric evaluation of BioFire FilmArray Pneumonia Panel for rapid bacteriological documentation of pneumonia
- Author
-
Jean-Sébastien Casalegno, Céline Monnard, Hanaa Benmansour, Stéphane Bonacorsi, Chloé Plouzeau, Agathe Becker, Guillaume Geslain, Camille d’Humières, Paul Duquaire, Catherine Neuwirth, Lauranne Broutin, Emmanuel Lecorche, Claude-Alexandre Gustave, Carole Lemarié, Laurence Armand-Lefevre, Emmanuelle Vigier, Adel Maamar, Jean-Philippe Lavigne, Jean-Pierre Quenot, Christophe Burucoa, Olivier Dauwalder, Gabriel Auger, Julie Cremniter, Alexy Tran-Dinh, Marion Baldeyrou, Hervé Jacquier, Maxime Pichon, Rafael Mahieu, Claire Poyart, Julien Loubinoux, Solen Kernéis, Manon Lejeune, Jean-François Timsit, Nabil Gastli, Bruno Lina, François Vandenesch, Achille Kouatchet, Vincent Cattoir, Pierre Saint-Sardos, Emmanuelle Cambau, Anthony Michaud, Sophie Alviset, André Boibieux, Aurélie Cointe, Gauthier Péan de Ponfilly, Grégory Destras, Robin Stéphan, Matthieu Daragon, Philippe Montravers, Michael Levy, Vincent Rzepecki, Hélène Pailhoriès, Service de Bactériologie [CHU Cochin, AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire de bactériologie (CHU Dijon), Plateau technique de Biologie [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Virulence bactérienne et maladies infectieuses (VBMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Clermont Auvergne (UCA), Service de Bactériologie [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques (HIFIH), Université d'Angers (UA), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Hôpital de la Milétrie, Centre hospitalier universitaire de Poitiers (CHU Poitiers), Institut des Agents Infectieux [Lyon] (IAI), Hospices Civils de Lyon (HCL), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Robert Debré, Laboratoire de Bactériologie et Hygiène Hospitalière [Rennes], CHU Pontchaillou [Rennes], Centre National de Référence de la Résistance aux Antibiotiques [CHU Rennes] (CNR), Hôpital Cochin [AP-HP], ARN régulateurs bactériens et médecine (BRM), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Meso Scale Diagnostics, The French FA-PP study group includes the following investigators: Sophie Alviset (Paris Cochin), Laurence Armand-Lefèvre (Paris Bichat), Marion Baldeyrou (Rennes), Agathe Becker (Hospices Civils de Lyon), André Boibieux (Hospices Civils de Lyon), Stéphane Bonacorsi (Paris, Robert-Debré), Christophe Burucoa (Poitiers), Emmanuelle Cambau (Paris Lariboisière), Jean-Sébastien Casalegno (Hospices Civils de Lyon), Aurélie Cointe (Paris, Robert-Debré), Julie Cremniter (Poitiers), Grégory Destras (Hospices Civils de Lyon), Paul Duquaire (Hospices Civils de Lyon), Guillaume Geslain (Paris, Robert-Debré), Claude-Alexandre Gustave (Hospices Civils de Lyon), Hervé Jacquier (Paris Lariboisière), Achille Kouatchet (Angers), Emmanuel Lecorche (Paris Lariboisière), Manon Lejeune (Paris Bichat), Bruno Lina (Hospices Civils de Lyon), Rafaël Mahieu (Angers), Adel Maamar (Rennes), Anthony Michaud (Poitiers), Céline Monnard (Hospices Civils de Lyon), Philippe Montravers (Paris Bichat), Catherine Neuwirth (Dijon), Gauthier Péan de Ponfilly (Paris, Lariboisière), Maxime Pichon (Poitiers), Chloé Plouzeau (Poitiers), Claire Poyart (Paris Cochin), Jean-Pierre Quenot (Dijon), Vincent Rzepecki (Nîmes), Robin Stéphan (Nîmes), Jean-François Timsit (Paris Bichat), Alexy Tran-Dinh (Paris Bichat), François Vandenesch (Hospices Civils de Lyon) and Emmanuelle Vigier (Paris Bichat)., Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), CHU Clermont-Ferrand, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Université Sorbonne Paris Nord, Pathogénie des Staphylocoques – Staphylococcal Pathogenesis (StaPath), Centre International de Recherche en Infectiologie - UMR (CIRI), Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
- Subjects
0301 basic medicine ,Microbiology (medical) ,medicine.medical_specialty ,Atypical bacteria ,Concordance ,[SDV]Life Sciences [q-bio] ,FilmArray pneumonia panel ,030106 microbiology ,Gastroenterology ,Lower respiratory tract infection ,03 medical and health sciences ,0302 clinical medicine ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Internal medicine ,Multiplex polymerase chain reaction ,Diagnosis ,medicine ,Pneumonia, Bacterial ,Humans ,030212 general & internal medicine ,medicine.diagnostic_test ,biology ,Bacteria ,business.industry ,General Medicine ,Syndromic panel ,Multiplex PCR ,medicine.disease ,biology.organism_classification ,3. Good health ,Pneumonia ,Infectious Diseases ,Bronchoalveolar lavage ,[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology ,Molecular Diagnostic Techniques ,Sputum ,medicine.symptom ,business ,Multiplex Polymerase Chain Reaction - Abstract
International audience; OBJECTIVES: To evaluate performances of the rapid multiplex PCR assay BioFire FilmArray Pneumonia Panel (FA-PP) for detection of bacterial pathogens and antibiotic resistance genes in sputum, endotracheal aspirate (ETA) and bronchoalveolar lavage (BAL) specimens. METHODS: This prospective observational study was conducted in 11 French university hospitals (July to December 2018) and assessed performance of FA-PP by comparison with routine conventional methods. RESULTS: A total of 515 respiratory specimens were studied, including 58 sputa, 217 ETA and 240 BAL. The FA-PP detected at least one pathogen in 384 specimens, yielding an overall positivity rate of 74.6% (384/515). Of them, 353 (68.5%) specimens were positive for typical bacteria while eight atypical bacteria and 42 resistance genes were found. While identifying most bacterial pathogens isolated by culture (374/396, 94.4%), the FA-PP detected 294 additional species in 37.7% (194/515) of specimens. The FA-PP demonstrated positive percentage agreement and negative percentage agreement values of 94.4% (95% CI 91.7%-96.5%) and 96.0% (95% CI 95.5%-96.4%), respectively, when compared with culture. Of FA-PP false-negative results, 67.6% (46/68) corresponded to bacterial species not included in the panel. At the same semi-quantification level (in DNA copies/mL for FA-PP versus in CFU/mL for culture), the concordance rate was 43.4% (142/327) for culture-positive specimens with FA-PP reporting higher semi-quantification of ≥1 log(10) in 48.6% (159/327) of cases. Interestingly, 90.1% of detected bacteria with ≥10(6) DNA copies/mL grew significantly in culture. CONCLUSIONS: FA-PP is a simple and rapid molecular test that could complement routine conventional methods for improvement of diagnosis accuracy of pneumonia.
- Published
- 2021
44. Shiga Toxin–Associated Hemolytic Uremic Syndrome in Adults, France, 2009–2017
- Author
-
Stéphane Bonacorsi, Matthieu Jamme, Alexandre Hertig, Elie Azoulay, David Ribes, Lila Bouadma, François-Xavier Weill, Julien Hogan, Aurélie Cointe, Antoine Dossier, Alain Wynckel, Eric Daugas, Benoit Travert, Agnès Veyradier, Yahsou Delmas, Patricia Mariani-Kurkdjian, Paul Coppo, Eric Rondeau, Gabriel Choukroun, Claire Presne, Miguel Hie, Emilie Cornec-Le Gall, Lionel Galicier, Steven Grangé, Sandrine Malot, Ygal Benhamou, Fadi Fakhouri, Véronique Frémeaux-Bacchi, and Amélie Seguin
- Subjects
food-borne infections ,Epidemiology ,medicine.medical_treatment ,Shiga toxin–producing Escherichia coli ,Infectious and parasitic diseases ,RC109-216 ,0302 clinical medicine ,030212 general & internal medicine ,bacteria ,Immunodeficiency ,Escherichia coli Infections ,biology ,Shiga-Toxigenic Escherichia coli ,Hazard ratio ,Shiga toxin ,Eculizumab ,thrombotic microangiopathy ,STEC ,food safety ,Infectious Diseases ,Cohort ,Medicine ,France ,medicine.drug ,Microbiology (medical) ,Adult ,medicine.medical_specialty ,Thrombotic microangiopathy ,030231 tropical medicine ,03 medical and health sciences ,Internal medicine ,medicine ,Escherichia coli ,Humans ,HUS ,Dialysis ,Retrospective Studies ,business.industry ,Research ,enteric infections ,E. coli ,Retrospective cohort study ,medicine.disease ,Shiga Toxin–Associated Hemolytic Uremic Syndrome in Adults, France, 2009–2017 ,Hemolytic-Uremic Syndrome ,biology.protein ,hemolytic uremic syndrome ,business - Abstract
We conducted a retrospective study on hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli (STEC) in 96 adults enrolled in the cohort of the National Reference Center for Thrombotic Microangiopathies network in France during 2009-2017. Most infections were caused by STEC strains not belonging to the O157 or O104 serogroups. Thirty (31.3%) patients had multiple risk factors for thrombotic microangiopathy. In total, 61 (63.5%) patients required dialysis, 50 (52.1%) had a serious neurologic complication, 34 (35.4%) required mechanical ventilation, and 19 (19.8%) died during hospitalization. We used multivariate analysis to determine that the greatest risk factors for death were underlying immunodeficiency (hazard ratio 3.54) and severe neurologic events (hazard ratio 3.40). According to multivariate analysis and propensity score-matching, eculizumab treatment was not associated with survival. We found that underlying conditions, especially immunodeficiency, are strongly associated with decreased survival in adults who have hemolytic uremic syndrome caused by STEC.
- Published
- 2021
45. Comparative genomic analysis of ESBL-producing Escherichia coli from faecal carriage and febrile urinary tract infection in children: a prospective multicentre study
- Author
-
Philippe Bidet, André Birgy, Naim Ouldali, Stéphane Béchet, Corinne Levy, Fouad Madhi, Elsa Sobral, Robert Cohen, and Stéphane Bonacorsi
- Abstract
Background The reliability of ESBL-producing Escherichia coli (ESBL-Ec) faecal carriage monitoring to guide probabilistic treatment of febrile urinary tract infection (FUTI) in children remains unclear. Objectives To compare the genomic characteristics of ESBL-Ec isolates from faecal carriage and FUTI to assess their correlation and identify a FUTI-associated virulence profile. Methods We conducted a prospective multicentre hospital and ambulatory-based study. We analysed the genotypes and virulence factors of both faecal and FUTI ESBL-Ec by whole genome sequencing. Correlations were assessed by non-parametric Spearman coefficient and virulence factors were assessed by chi-squared tests with Bonferroni correction. Results We included 218 ESBL-Ec causing FUTI and 154 ESBL-Ec faecal carriage isolates. The most frequent ST was ST131 (44%) in both collections. We found high correlation between carriage and ESBL-Ec FUTI regarding genes/alleles (rho = 0.88, P Conclusions The genomic profile of ESBL-Ec causing FUTI in children strongly correlates with faecal carriage isolates except for a few genes. The presence of papGII and/or traJ in a previously identified carriage strain could be used as a marker of uropathogenicity and may guide the empirical antimicrobial choice in subsequent FUTI.
- Published
- 2022
46. Reassessing the performance of the 'step-by-step' approach to febrile infants aged 90 days and younger in the context of the COVID-19 pandemic: a multicentric retrospective study
- Author
-
Alexis Rybak, Camille Aupiais, Marie Cotillon, Romain Basmaci, Loïc de Pontual, Stéphane Bonacorsi, Patricia Mariani, Luce Landraud, Ségolène Brichler, Isabelle Poilane, Naïm Ouldali, and Luigi Titomanlio
- Abstract
BackgroundInfants with COVID-19 can often present with fever without source which is a challenging situation in infants < 90 days old. The “step-by-step” algorithm has been proposed to identify children at high risk of bacterial infection. In the context of the COVID-19 pandemic, we aimed to reassess the diagnostic performance of this algorithm.MethodsWe performed a multicentric retrospective study in 3 French pediatric emergency departments between 2018 and 2020. We applied the “step-by-step” algorithm to four clinical entities: COVID-19, febrile urinary tract infections (FUTI), invasive bacterial infection (IBI), and enterovirus infections. The main outcome was the proportion of infants classified at high risk.ResultsAmong the 199 infants included, 40 had isolated COVID-19, 25 had IBI, 60 had FUTI, and 74 had enterovirus infection. All but one infant with bacterial infection were classified at high risk (96% for IBI and 100% for FUTI) as well as 95% with enterovirus and 82% with COVID-19. Infants with COVID-19 were classified at high risk because an ill appearance (72%), an age ≤ 21 days (27%) and/or leukocyturia (19%). All these infants had procalcitonin values < 0.5 ng/mL and only one had C-reactive protein level > 20 mg/L.ConclusionsThe “step-by-step” algorithm remains effective to identify infants with bacterial infection but misclassifies most infants with COVID-19 as at high risk of bacterial infection leading to unnecessary cares. An updated algorithm based adding viral testing may be needed to discriminate fever related to isolated COVID-19 in infants < 90 days old.
- Published
- 2022
47. Escherichia coli community-acquired meningitis in adults: a case series of 29 patients in France
- Author
-
Aurore Moussiegt, André Birgy, Aurélie Cointe, Xavier Duval, Philippe Bidet, and Stéphane Bonacorsi
- Subjects
Microbiology (medical) ,Adult ,Community-Acquired Infections ,Infectious Diseases ,Meningitis, Escherichia coli ,Escherichia coli ,Humans ,Meningitis ,General Medicine ,France ,Escherichia coli Infections - Published
- 2022
48. Emergence of Kawasaki disease related to SARS-CoV-2 infection in an epicentre of the French COVID-19 epidemic: a time-series analysis
- Author
-
Luigi Titomanlio, Kostas Danis, Constance Beyler, Ulrich Meinzer, Stéphane Bonacorsi, Jean Gaschignard, Isabelle Melki, Laure Maurice, Marion Caseris, Albert Faye, Fleur Le Bourgeois, Julie Poline, Audrey Blachier, Patricia Mariani, Naim Ouldali, Maryline Chomton, Robert Cohen, Marie Pouletty, AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université de Paris (UP), Epidémiologie Clinique et Evaluation Economique Appliquées aux Populations Vulnérables (ECEVE (U1123 / UMR_S_1123)), Institut National de la Santé et de la Recherche Médicale (INSERM)-AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université de Paris (UP), Université de Paris - UFR Médecine [Santé] (UP Médecine), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Université Sorbonne Paris Nord, Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), CHU Necker - Enfants Malades [AP-HP], Université Paris Cité (UPCité), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Cité (UPCité), Université Paris Cité - UFR Médecine [Santé] (UPCité UFR Médecine), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), and CCSD, Accord Elsevier
- Subjects
Pediatrics ,medicine.medical_specialty ,[SDV]Life Sciences [q-bio] ,Pneumonia, Viral ,Disease ,Mucocutaneous Lymph Node Syndrome ,Article ,Betacoronavirus ,03 medical and health sciences ,0302 clinical medicine ,030225 pediatrics ,Pandemic ,Developmental and Educational Psychology ,medicine ,Humans ,Pediatrics, Perinatology, and Child Health ,030212 general & internal medicine ,skin and connective tissue diseases ,Pandemics ,ComputingMilieux_MISCELLANEOUS ,SARS-CoV-2 ,business.industry ,Incidence (epidemiology) ,COVID-19 ,Outbreak ,Retrospective cohort study ,Emergency department ,medicine.disease ,3. Good health ,[SDV] Life Sciences [q-bio] ,Pneumonia ,Phenotype ,Pediatrics, Perinatology and Child Health ,Kawasaki disease ,Coronavirus Infections ,business - Abstract
Summary Background Kawasaki disease is an acute febrile systemic childhood vasculitis, which is suspected to be triggered by respiratory viral infections. We aimed to examine whether the ongoing COVID-19 epidemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is associated with an increase in the incidence of Kawasaki disease. Methods We did a quasi-experimental interrupted time series analysis over the past 15 years in a tertiary paediatric centre in the Paris region, a French epicentre of the COVID-19 outbreak. The main outcome was the number of Kawasaki disease cases over time, estimated by quasi-Poisson regression. In the same centre, we recorded the number of hospital admissions from the emergency department (2005–2020) and the results of nasopharyngeal multiplex PCR to identify respiratory pathogens (2017–2020). These data were compared with daily hospital admissions due to confirmed COVID-19 in the same region, recorded by Public Health France. Findings Between Dec 1, 2005, and May 20, 2020, we included 230 patients with Kawasaki disease. The median number of Kawasaki disease hospitalisations estimated by the quasi-Poisson model was 1·2 per month (IQR 1·1–1·3). In April, 2020, we identified a rapid increase of Kawasaki disease that was related to SARS-CoV-2 (six cases per month; 497% increase [95% CI 72–1082]; p=0·0011), starting 2 weeks after the peak of the COVID-19 epidemic. SARS-CoV-2 was the only virus circulating intensely during this period, and was found in eight (80%) of ten patients with Kawasaki disease since April 15 (SARS-CoV-2-positive PCR or serology). A second peak of hospital admissions due to Kawasaki disease was observed in December, 2009 (six cases per month; 365% increase ([31–719]; p=0.0053), concomitant with the influenza A H1N1 pandemic. Interpretation Our study further suggests that viral respiratory infections, including SAR-CoV-2, could be triggers for Kawasaki disease and indicates the potential timing of an increase in incidence of the disease in COVID-19 epidemics. Health-care providers should be prepared to manage an influx of patients with severe Kawasaki disease, particularly in countries where the peak of COVID-19 has recently been reached. Funding French National Research Agency.
- Published
- 2020
49. The population genetics of pathogenic Escherichia coli
- Author
-
Stéphane Bonacorsi, Olivier Clermont, David M. Gordon, and Erick Denamur
- Subjects
Genetics ,0303 health sciences ,education.field_of_study ,General Immunology and Microbiology ,biology ,030306 microbiology ,Population ,Virulence ,biology.organism_classification ,medicine.disease_cause ,Microbiology ,Genome ,03 medical and health sciences ,Infectious Diseases ,Phylogenetics ,Pathogenic Escherichia coli ,medicine ,Epistasis ,Mobile genetic elements ,education ,Escherichia coli - Abstract
Escherichia coli is a commensal of the vertebrate gut that is increasingly involved in various intestinal and extra-intestinal infections as an opportunistic pathogen. Numerous pathotypes that represent groups of strains with specific pathogenic characteristics have been described based on heterogeneous and complex criteria. The democratization of whole-genome sequencing has led to an accumulation of genomic data that render possible a population phylogenomic approach to the emergence of virulence. Few lineages are responsible for the pathologies compared with the diversity of commensal strains. These lineages emerged multiple times during E. coli evolution, mainly by acquiring virulence genes located on mobile elements, but in a specific chromosomal phylogenetic background. This repeated emergence of stable and cosmopolitan lineages argues for an optimization of strain fitness through epistatic interactions between the virulence determinants and the remaining genome.
- Published
- 2020
50. Invasive Disease Potential of Pneumococcal Serotypes in Children After PCV13 Implementation
- Author
-
Naim Ouldali, Stéphane Béchet, Marie Goldrey, Emmanuelle Varon, Robert M. Cohen, Stéphane Bonacorsi, and Corinne Levy
- Subjects
0301 basic medicine ,Microbiology (medical) ,Pneumococcal serotypes ,Serotype ,Vaccines, Conjugate ,Invasive disease ,business.industry ,Infant ,Serogroup ,medicine.disease ,Virology ,Pneumococcal Infections ,Pneumococcal Vaccines ,03 medical and health sciences ,Pneumococcal infections ,Streptococcus pneumoniae ,030104 developmental biology ,0302 clinical medicine ,Infectious Diseases ,Humans ,Medicine ,030212 general & internal medicine ,Child ,business - Abstract
We aimed to assess the invasive disease potential of non-PCV13 serotypes after the implementation of this vaccine. Most non-PCV13 serotypes had low invasive disease potential. Among serotypes with the highest invasive disease potential (12F, 24F, 38, 8, 33F, 22F, and 10A), all but 24F and 38 were included in PCV20.
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.